Opendata, web and dolomites

DILITEST

Diagnosis and Exclusion of Drug-Induced Liver Injury by using Patient Blood Samples (DILITEST)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "DILITEST" data sheet

The following table provides information about the project.

Coordinator
METAHEPS GMBH 

Organization address
address: AM KLOPFERSPITZ 19
city: PLANEGG
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.metaheps.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-12-01   to  2016-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    METAHEPS GMBH DE (PLANEGG) coordinator 50˙000.00

Map

 Project objective

Ca. 1 billion USD are lost by late stage failures per one successfully marketed drug. Idiosyncratic Drug induced Liver injury (iDILI) is one of the major causes for late stage failures and also can have serious consequences for the patient like death or the need for liver transplantation. iDILI occurs only in susceptible patients regardless of drug dosage or latency and is not predictable from preclinical in vitro or animal testing. Usually it occurs during late stage clinical phases, when hundreds of millions of USD were already invested in the drug. Therefore, iDILI is a significant challenge for patients, drug-developers and regulatory bodies. Until now there is no valid test available that allows to positively diagnose or exclude a drug as iDILI cause, resulting in incorrect market withdrawals or project terminations. Since the majority of patients would tolerate the drug, these patients are deprived from innovative treatment options. DILITEST aims to develop a test to diagnose iDILI in individual patients and identify the causaltive drug. The test is based on a patented method to generate liver cell-like cells from a blood sample. This will allow to prevent investment losses by incorrect market withdrawals or terminations and solve the dilemma of iDILI for patients, pharmaceutical industry and regulatory bodies by enabling marketing of safe drugs and avoiding incorrect terminations. Overall objective of DILITEST is to market the highly innovative test by MetaHeps GmbH after validation in independent cohorts of european and american registries led by international experts in the field of iDILI research. MetaHeps GmbH will provide the unrivaled technology as a service to pharmaceutical industry with focus on the still growing high volume clinical trial market, allowing its customers to prevent late stage failures by either excluding the drug as a cause for iDILI or the possibility to make use of the novel test to identify novel saftey biomarkers.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DILITEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DILITEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More